Compare Globus Medical Inc. Class A Common Stock (GMED) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs STMicroelectronics NV — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while STMicroelectronics NV trades at $44.6 (market cap $43.15B). The key difference: STMicroelectronics NV is far larger — about 4.2× Globus Medical Inc. Class A Common Stock's market cap, and STMicroelectronics NV pays a 0.77% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and STMicroelectronics NV for 65 Days on average.
| GMED | STM | |
|---|---|---|
Market Cap | $10.25B | $43.15B |
Volume | 1,059,528 | 14,115,128 |
Sector | Health | Technology |
52-Week High | $96.82 | $79.91 |
52-Week Low | $58.33 | $21.20 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $9.76B | $40.67B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
STM trades at $49.57, down 1.8% on the day, with a bearish technical signal but strong analyst support. The company reported mixed Q2 2026 earnings, beating expectations with $0.31 EPS versus $0.26 expected, while revenue trends show recovery with 26% year-on-year growth in Q2. Valuation metrics appear elevated with a P/E of 94.59, but the company maintains solid cash flow and a strong balance sheet with $6.18 billion in cash.
STM faces near-term profitability challenges with negative net income margins, but strong AI data-center revenue growth projections to exceed $2 billion by 2027 provide upside potential. Key risks include execution on margin improvement and competitive pressures in semiconductor markets. Analyst consensus remains bullish with a $77.31 price target representing 56% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
